New antibody combo for COVID-19 passes early safety check
NCT ID NCT05181683
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested whether a combination of two antibodies (casirivimab and imdevimab) is safe and tolerable in healthy adults. Forty-five volunteers received the antibodies either as a shot under the skin or through an IV. The main goal was to check for side effects, not to treat or prevent COVID-19. The study is complete and helps guide future research.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Regeneron Study Site
Miami, Florida, 33186, United States
-
Regeneron StudySite
Winter Park, Florida, 32789, United States